Sign in Create account

Ajanta Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AJANTPHARM BSE: 532331
₹3620.80
▲ 63.30 (1.78%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
90/100
Strong
Valuation
—/100
Expensive
Momentum
86/100
Bullish

QVM read Quality in motion Quality Strong, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Ajanta Pharma Limited (APL) is an Indian multinational pharmaceutical company. The company operates in India, the United States, and over 30 countries across Africa, Southeast Asia, West Asia, and the CIS. It was established in 1973..

Source: Wikipedia

Key Metrics

Market Capitalization
₹45,237 Cr
PE (TTM)
44.9
Industry median 36.1 (152 companies)
Price to Book
10.0
PEG (TTM)
5.7
Institutions holding %
29.48%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
17.0
Relative return vs Sector, qtr %
8.2
Free Cash Flow
₹164 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
23.71%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
7.64%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
15.11%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
23.73%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
23.18%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.64
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.05
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
324.29
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
21.19%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
28.50%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
25.94%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
17.16%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
29.41%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
23.33%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

5 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.05)
  • Yes Return on equity is 15% or more (23.3%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (22.5% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Sell Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.8%
Low 3567.1000 · High 3758.9000
1W return
1.5%
Low 3500.0000 · High 3758.9000
1M return
0.5%
Low 3425.0000 · High 3758.9000
52W return
51.0%
Low 2379.3000 · High 3796.0000
Lifetime High ₹3718.2000 (Aug. 17, 2026)
Lifetime Low ₹21.6000 (March 31, 2003)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
3569.6
10D
3554.9
20D
3546.2
50D
3497.7
100D
3370.7
200D
3097.2

Delivery and volume

Day avg. delivery
46.1%
Week avg. delivery
40.8%
Month avg. delivery
52.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

3648.93
Pivot
First resistance3730.77
Second resistance3840.73
Third resistance3922.57
First support3538.97
Second support3457.13
Third support3347.17
Day RSI59.3
Day MFI56.3
Day MACD10.85
Day MACD signal5.77

Beta

1M0.38
3M0.50
1Y0.51
3Y0.46

Price change analysis

↑ 0.5%
Over 1 Month
LowHigh
3425.003758.90
↑ 8.2%
Over 3 Months
LowHigh
3254.803796.00
↑ 28.5%
Over 6 Months
LowHigh
2696.603796.00
↑ 51.0%
Over 1 Year
LowHigh
2379.303796.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 44.9 (own history: 31.7–47.1)
Sell Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹1,489 Cr
Net profit (June 30, 2026)
₹315 Cr
Basic EPS (June 30, 2026)
₹25.2500

Ranks #19 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter63.48%
  • Mutual funds18.10%
  • FII/FPI7.68%
  • Other DII3.70%
  • Public7.04%

Largest holders

NameCategoryShares %Shares
Rajesh M Agrawal, trustee Rajesh Agrawal TrustPromoter14.4700%18078148
Yogesh M Agrawal, trustee Yogesh Agrawal TrustPromoter14.4700%18078147
Aayush M Agrawal, trustee Aayush Agrawal TrustPromoter11.3000%14112924
Ravi P Agrawal, trustee Ravi Agrawal TrustPromoter10.2400%12792904
Gabs Investments Pvt LtdPromoter10.0800%12588393

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 66.25% to 63.48% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 8.26% to 7.68% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 15.22% to 18.10% in Jun 2026 qtr

51 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 412 insider trades, 35 SAST, 431 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
13 Mar 2026 SHAILESH R SINGH Other Sell 0 ₹0
29 Dec 2025 SHAILESH R SINGH Other Sell 0 ₹0
13 Nov 2025 SHAILESH R SINGH Other Sell 0 ₹0
13 Nov 2025 SHAILESH R SINGH Other Sell 0 ₹0
26 Jun 2025 SHAILESH R SINGH Other Sell 0 ₹0
28 Feb 2025 VANDANA SHAILESH SINGH Other Sell 0 ₹0
31 Dec 2024 J K TRIPATHI Other Sell 0 ₹0
31 Dec 2024 J K TRIPATHI Other Sell 0 ₹0
31 Dec 2024 J K TRIPATHI Other Sell 0 ₹0
31 Dec 2024 J K TRIPATHI Other Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 180 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
9 Jun 2026 RAVI AGRAWAL TRUST Block Sell 3,450,000 2968.0000 NSE
9 Jun 2026 KOTAK MAHINDRA MUTUAL FUND Block Buy 2,102,291 2968.0000 NSE
9 Jun 2026 ADITYA BIRLA SUN LIFE MUTUAL FUND Block Buy 1,347,709 2968.0000 NSE
9 Jun 2026 RAVI AGRAWAL TRUST Bulk Sell 3,450,000 2968.0000 NSE
9 Jun 2026 KOTAK MAHINDRA MUTUAL FUND Bulk Buy 2,102,291 2968.0000 NSE
9 Jun 2026 RAVI AGRAWAL TRUST Block Sell 3,450,000 2968.0000 NSE
9 Jun 2026 KOTAK MAHINDRA MUTUAL FUND Block Buy 2,102,291 2968.0000 NSE
9 Jun 2026 ADITYA BIRLA SUN LIFE MUTUAL FUND Block Buy 1,347,709 2968.0000 NSE
25 Jan 2024 MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND Block Buy 2,685 2195.5000 BSE
25 Jan 2024 MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND Block Buy 47,901 2195.5000 BSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
30 Jul 2026 Dividend —
30 Jul 2026 Financial Results Yes
5 May 2026 Financial Results Yes
30 Jan 2026 Financial Results Yes
3 Nov 2025 Dividend —

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Insider Trading / SAST Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
30 Sep 2026 Company Update Ajanta Pharma Ltd - 532331 - Submission Of Sustainability Report For FY 2026
28 Sep 2026 Insider Trading / SAST Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
25 Sep 2026 Insider Trading / SAST Ajanta Pharma Ltd - 532331 - Closure of Trading Window
18 Sep 2026 Insider Trading / SAST Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (21.2%)
  • Low financial leverage (Debt/Equity 0.05)
  • Comfortable interest coverage (324.3x)
  • Healthy liquidity (Current Ratio 2.64)
  • Strong revenue growth YoY (23.2%)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (44.9) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Single-stock futures available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.

Part of: NIFTY 500, NIFTY 500, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY PHARMA, NIFTY PHARMA

Frequently asked questions about Ajanta Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.